QGA
ASND icon

Q Global Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Q Global Advisors’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.38M Hold
41,000
– – 5.98% 9
2026
Q1 		$9.38M Buy
+41,000
New +$9.19M 8.27% 5

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Q Global Advisors's ASND Position: Q2 2026 in Review

Q Global Advisors held its Ascendis Pharma A/S (ASND) position steady in Q2 2026 at 100,000 shares worth $26.7M. The position accounts for 17.01% of the portfolio, ranked #1.

Q Global Advisors first reported a position in ASND in Q4 2020 and has held it in 23 quarters since. The position peaked at $44M in Q2 2025. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

  • Q Global Advisors held 100,000 shares of Ascendis Pharma A/S worth $26.7M as of Q2 2026.
  • Q Global Advisors left its Ascendis Pharma A/S share count unchanged in Q2 2026.
  • Ascendis Pharma A/S made up 17.01% of Q Global Advisors's portfolio in Q2 2026, its #1 holding.
  • Q Global Advisors first reported a position in Ascendis Pharma A/S in Q4 2020 and has held it in 23 quarters since.
  • Q Global Advisors's Ascendis Pharma A/S position peaked at $44M in Q2 2025.
  • 313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Q Global Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.